<?xml version='1.0' encoding='utf-8'?>
<document id="28710808"><sentence text="The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy."><entity charOffset="141-152" id="DDI-PubMed.28710808.s1.e0" text="piperaquine" /></sentence><sentence text="Antimalarial therapy during pregnancy poses important safety concerns due to potential teratogenicity and maternal physiological and biochemical changes during gestation" /><sentence text=" Piperaquine (PQ) has gained interest for use in pregnancy in response to increasing resistance towards sulfadoxine-pyrimethamine in sub-Saharan Africa"><entity charOffset="1-12" id="DDI-PubMed.28710808.s3.e0" text="Piperaquine" /><entity charOffset="14-16" id="DDI-PubMed.28710808.s3.e1" text="PQ" /><entity charOffset="116-129" id="DDI-PubMed.28710808.s3.e2" text="pyrimethamine" /><pair ddi="false" e1="DDI-PubMed.28710808.s3.e0" e2="DDI-PubMed.28710808.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28710808.s3.e0" e2="DDI-PubMed.28710808.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28710808.s3.e0" e2="DDI-PubMed.28710808.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28710808.s3.e1" e2="DDI-PubMed.28710808.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28710808.s3.e1" e2="DDI-PubMed.28710808.s3.e2" /></sentence><sentence text=" Coinfection with HIV is common in many developing countries, however, little is known about the impact of antiretroviral (ARV) mediated drug-drug interaction (DDI) on piperaquine pharmacokinetics during pregnancy"><entity charOffset="168-179" id="DDI-PubMed.28710808.s4.e0" text="piperaquine" /></sentence><sentence text=" This study applied mechanistic pharmacokinetic modelling to predict pharmacokinetics in non-pregnant and pregnant patients, which was validated in distinct customised population groups from Thailand, Sudan and Papua New Guinea" /><sentence text=" In each population group, no significant differences in day 7 concentrations were observed during different gestational weeks (GW) (weeks 10-40), supporting the notion that piperaquine is safe throughout pregnancy with consistent pharmacokinetics, although possible teratogenicity may limit this"><entity charOffset="174-185" id="DDI-PubMed.28710808.s6.e0" text="piperaquine" /></sentence><sentence text=" Antiretroviral-mediated DDIs (efavirenz and ritonavir) had moderate effects on piperaquine during different gestational weeks with a predicted AUCratio in the range 0"><entity charOffset="31-40" id="DDI-PubMed.28710808.s7.e0" text="efavirenz" /><entity charOffset="45-54" id="DDI-PubMed.28710808.s7.e1" text="ritonavir" /><entity charOffset="80-91" id="DDI-PubMed.28710808.s7.e2" text="piperaquine" /><pair ddi="false" e1="DDI-PubMed.28710808.s7.e0" e2="DDI-PubMed.28710808.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28710808.s7.e0" e2="DDI-PubMed.28710808.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28710808.s7.e0" e2="DDI-PubMed.28710808.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28710808.s7.e1" e2="DDI-PubMed.28710808.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28710808.s7.e1" e2="DDI-PubMed.28710808.s7.e2" /></sentence><sentence text="56-0" /><sentence text="8 and 1" /><sentence text="64-1" /><sentence text="79 for efavirenz and ritonavir, respectively, over GW 10-40, with a reduction in circulating human serum albumin significantly reducing the number of subjects attaining the day 7 (post-dose) therapeutic efficacy concentrations under both efavirenz and ritonavir DDIs"><entity charOffset="7-16" id="DDI-PubMed.28710808.s11.e0" text="efavirenz" /><entity charOffset="21-30" id="DDI-PubMed.28710808.s11.e1" text="ritonavir" /><entity charOffset="238-247" id="DDI-PubMed.28710808.s11.e2" text="efavirenz" /><entity charOffset="252-261" id="DDI-PubMed.28710808.s11.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e0" e2="DDI-PubMed.28710808.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e0" e2="DDI-PubMed.28710808.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e0" e2="DDI-PubMed.28710808.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e0" e2="DDI-PubMed.28710808.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e1" e2="DDI-PubMed.28710808.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e1" e2="DDI-PubMed.28710808.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e1" e2="DDI-PubMed.28710808.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e2" e2="DDI-PubMed.28710808.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28710808.s11.e2" e2="DDI-PubMed.28710808.s11.e3" /></sentence><sentence text=" This present model successfully mechanistically predicted the pharmacokinetics of piperaquine in pregnancy to be unchanged with respect to non-pregnant women, in the light of factors such as malaria/HIV co-infection"><entity charOffset="83-94" id="DDI-PubMed.28710808.s12.e0" text="piperaquine" /></sentence><sentence text=" However, antiretroviral-mediated DDIs could significantly alter piperaquine pharmacokinetics"><entity charOffset="65-76" id="DDI-PubMed.28710808.s13.e0" text="piperaquine" /></sentence><sentence text=" Further model refinement will include collation of relevant physiological and biochemical alterations common to HIV/malaria patients" /><sentence text="" /></document>